Investor Presentaiton
Our Strive25 strategy
supports continued long-
term value creation through
revenue and earnings growth
Long-term financial guidance
مرا
100
8-10%
organic growth
p.a.1
more than 30%
EBIT margin
beyond 2024/252
1 Raised to 8-10%, from previously 7-9%, on July 7 as a result of the acquisition of Kerecis, expected to contribute
around 1%-point to group organic growth as of FY 2024/25.
2 For the remaining Strive25 strategic period running until end 2024/25, the EBIT margin is now expected to
remain below 30%, and assumes dilution of around 100 basis points p.a. from Kerecis (including PPA amortisation)
23
Interventional
Urology
Innovation
Ostomy
Care
J
Continence
Care
Strive
25
SUSTAINABLE
GROWTH
LEADERSHIP
Wound and
Skin Care
(o
Voice and
Respiratory Care
*
Leadership, culture
and organization
Efficiency
Sustainability
ColoplastView entire presentation